On December 16, 2021, “Apatinib vs Placebo in Patients with Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer”, the phase III multi-center, randomized, double-blind, placebo-controlled phase III clinical study (REALITY...